AbbVie Upadacitinib Trial Meets Primary, Secondary Endpoints
June 29 2021 - 9:05AM
Dow Jones News
By Chris Wack
AbbVie Inc. said that upadacitinib 15 mg or 30 mg, once daily,
met the primary endpoint of clinical remission and all secondary
endpoints at one-year in a Phase 3 ulcerative colitis maintenance
study.
The pharmaceutical company said significantly more
upadacitinib-treated patients achieved clinical remission at week
52 compared to placebo.
In the study, adults with moderate to severe ulcerative colitis
who achieved a clinical response following an 8-week study period
of once-daily upadacitinib induction treatment were re-randomized
to receive upadacitinib 15 mg, upadacitinib 30 mg or placebo for an
additional 52 weeks.
All secondary endpoints were met, including the achievement of
endoscopic improvement, histologic-endoscopic mucosal improvement
and corticosteroid-free clinical remission at week 52. 49% of
patients treated with upadacitinib 15 mg and 62% of patients
treated with upadacitinib 30 mg achieved endoscopic improvement at
52 weeks versus 14% of patients in the placebo group. In addition,
35% of patients on upadacitinib 15 mg and 49% of patients on
upadacitinib 30 mg achieved HEMI, compared to 12% of patients in
the placebo group.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 29, 2021 08:50 ET (12:50 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024
